Featured Trial:
Melanoma Treatment

Featured Trial:
Head and Neck Cancer Treatment

Featured Trial:
Breast Cancer Treatment

Featured Trial:
Sarcoma Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

March 8, 2023

Categories

News Stories

The ComboMATCH patient registration trial and three treatment trials are now open

February 27, 2023

Categories

The TAILORx trial continues to provide reassurance that many women with early breast cancer can safely forego chemotherapy

February 23, 2023

Categories

News Stories

A focus on the DREAMseq trial reveals data-driven clinical insights into the selection of first-line treatment options for patients with BRAF-mutated metastatic melanoma

February 15, 2023

Categories

Announcements

A participant in the E1910 trial shares her experience in a Penn Medicine feature story with her hematologist, Dr. Selina Luger

February 15, 2023

Categories

News Stories

ASCO Living Guideline says ‘no’ to anti-VEGF-chemo combo in non-small cell lung cancer without driver alterations, based on data from the E5508 trial

February 10, 2023

Categories

The January/February 2023 News from ECOG-ACRIN blog is now available

February 10, 2023

Categories

Announcements

ECOG-ACRIN announces the Remarkable Mentor to Women in Oncology Award (nominations are due March 9)

February 9, 2023

Categories

Announcements

The application period is now open for Spring Meeting Attendance Awards for minority trainees

February 6, 2023

Categories

News Stories

Ongoing Trial: The INSIGNA clinical trial is testing the timing of immunotherapy alone or with chemotherapy for patients with advanced lung cancer

Posts

ECOG-ACRIN Cancer Research Group Follow 7,817 6,296

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

Retweet on Twitter ECOG-ACRIN Cancer Research Group Retweeted

; Petros Grivas @PGrivasMDPhD ·

15 Mar 1900973588150448428

Honored to serve in my new role as co-chair of @eaonc GU committee working with amazing @NaomiHaas5 & stellar colleagues nationwide! Have been in @eaonc for 11 years: huge progress, many opportunities ahead!
@MonikaJoshimd @fredhutch @HutchPresident @nicoleflemingmd
@OncoAlert

Reply on Twitter 1900973588150448428 Retweet on Twitter 1900973588150448428 15 Like on Twitter 1900973588150448428 120 Twitter 1900973588150448428

; ECOG-ACRIN Cancer Research Group @eaonc ·

20h 1901695242728017948

#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart of @URMC_DeptMed & @WilmotCancer, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM

Reply on Twitter 1901695242728017948 Retweet on Twitter 1901695242728017948 0 Like on Twitter 1901695242728017948 0 Twitter 1901695242728017948

; ECOG-ACRIN Cancer Research Group @eaonc ·

21h 1901681564657807814

“There has been ongoing controversy about whether ASCT still provides meaningful survival benefits in the modern treatment landscape.” -Timothy S. Fenske, MD, MS on EA4151 clinical trial results - mantle cell lymphoma via @ascopost

Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma...

Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma ...

ascopost.com

Reply on Twitter 1901681564657807814 Retweet on Twitter 1901681564657807814 0 Like on Twitter 1901681564657807814 1 Twitter 1901681564657807814

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).